Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists for Atrial Fibrillation in Patients With Liver Cirrhosis: An Update Systematic Review and Meta-analysis
- PMID: 40256444
- PMCID: PMC12008528
- DOI: 10.1016/j.jceh.2025.102534
Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists for Atrial Fibrillation in Patients With Liver Cirrhosis: An Update Systematic Review and Meta-analysis
Abstract
Background: This meta-analysis aimed to compare the efficacy and safety of direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) in patients with concomitant atrial fibrillation (AF) and liver cirrhosis (LC).
Methods: PubMed, Cochrane Library, Embase, Scopus, Web of Science, and China National Knowledge Infrastructure (CNKI) databases were searched for randomized clinical trials (RCTs) and non-RCTs comparing DOACs and VKAs in patients with AF and LC. Analyses were performed in R software. A random-effects model was employed to calculate the pooled hazard ratio (HR).
Results: Eleven studies encompassing 19,617 patients were included, with 9379 receiving DOACs and 10,238 receiving VKAs. DOACs were associated with a significant reduction in the incidence of major bleeding (HR 0.70; 95% CI: 0.61-0.81; P < 0.001; I2 = 0%), all-cause mortality (HR 0.87; 95% CI: 0.78-0.98; P = 0.022; I2 = 41%), and gastrointestinal bleeding (HR 0.75; 95% CI: 0.67-0.84; P < 0.001; I2 = 4%). No significant difference was observed for thromboembolic events (HR 0.86; 95% CI: 0.69-1.06; P = 0.153; I2 = 0%).
Conclusion: DOACs may be a feasible option for patients with AF and LC, demonstrating similar effectiveness to VKAs while exhibiting a better safety profile. These findings await validation by prospective studies.
Keywords: atrial fibrillation; direct oral anticoagulants; liver cirrhosis; meta-analysis; vitamin K antagonists.
© 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28. Clin Ther. 2017. PMID: 28668628
-
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis.Eur J Clin Pharmacol. 2023 Apr;79(4):461-471. doi: 10.1007/s00228-023-03463-x. Epub 2023 Feb 16. Eur J Clin Pharmacol. 2023. PMID: 36795127
-
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.Cochrane Database Syst Rev. 2018 Jun 19;6(6):CD006650. doi: 10.1002/14651858.CD006650.pub5. Cochrane Database Syst Rev. 2018. PMID: 29920657 Free PMC article.
-
An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.Am J Cardiol. 2023 Nov 1;206:132-150. doi: 10.1016/j.amjcard.2023.07.141. Epub 2023 Sep 11. Am J Cardiol. 2023. PMID: 37703679
-
Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis.Clin Res Cardiol. 2025 Jul 28. doi: 10.1007/s00392-025-02711-7. Online ahead of print. Clin Res Cardiol. 2025. PMID: 40719909
Cited by
-
Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis.Front Pharmacol. 2025 Jul 14;16:1620394. doi: 10.3389/fphar.2025.1620394. eCollection 2025. Front Pharmacol. 2025. PMID: 40727096 Free PMC article.
References
-
- Joglar José A., Chung M.K., Armbruster A.L., et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American heart association Joint committee on clinical Practice guidelines. Circulation. 2024;149 doi: 10.1161/CIR.0000000000001193. - DOI - PMC - PubMed
-
- January C.T., Samuel Wann L., Calkins H., et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American heart association task force on clinical Practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140 doi: 10.1161/CIR.0000000000000665. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources